Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 1.00 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863566 | 0.90 | PTGDR2 (0.81) | PTGDR2DHCR7PKMPTGDR | |
| SCHEMBL10175771 | 0.88 | PTGDR2 (0.79) | PTGDR2PKM | |
| SCHEMBL10175886 | 0.88 | PTGDR2 (0.79) | PTGDR2DHCR7 | |
| SCHEMBL10175899 | 0.88 | PTGDR2 (0.78) | PTGDR2DHCR7PKMPTGDR | |
| SCHEMBL863373 | 0.88 | PTGDR2 (0.81) | PTGDR2DHCR7PKMPTGDR | |
| SCHEMBL10225941 | 0.87 | PTGDR2 (0.77) | PTGDR2DHCR7PKMPTGDR | |
| SCHEMBL841154 | 0.87 | PTGDR2 (0.77) | PTGDR2DHCR7PKMPTGDR | |
| SCHEMBL10175778 | 0.86 | PTGDR2 (1.00) | PTGDR2DHCR7PTGDR | |
| SCHEMBL10175789 | 0.86 | PTGDR2 (1.00) | PTGDR2DHCR7PTGDR | |
| SCHEMBL10175807 | 0.86 | PTGDR2 (1.00) | PTGDR2DHCR7PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | PTGDR2 7/4885DHCR7 760/4885PKM 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.